Receive alerts
Market Cap:
£95.01 billion
52 weeks high
52 weeks low

Viewing results 1-25 of 350


AstraZeneca’s cancer drug combo stumbles in phase III lung cancer trial

Astra had been hoping to show that the combination of Imfinzi and tremelimumab was more effective in treating certain lung cancer patients than chemo...

54 minutes ago

AstraZeneca nears £100bn market cap as remarkable drug pipeline turnaround continues

Only five years ago, AstraZeneca’s Symbicort inhaler generated more sales than all of the firm’s cancer drugs combined. The same can’t be said any more…...

17 hours, 20 minutes ago

AstraZeneca pumps higher as Farxiga shows benefit in late-stage heart-failure study

Farxiga, when combined with current standard of care, was able to reduce the risk of cardiovascular death and the worsening of heart failure...

23 hours, 12 minutes ago

AstraZeneca’s Lynparza meets primary endpoint in late-stage ovarian cancer trial

AstraZeneca is competing with GSK to win the race to become the go-to maintenance treatment for people who have been treated for ovarian cancer...

6 days, 19 hours ago

Acasti Pharma reiterated as Speculative Buy by Mackie after FDA setback news for competitor Amarin

Amarin had recently indicated that they did not think they would need an FDA adcom meeting for their sNDA (supplemental new drug application) for Vascepa...

1 week, 5 days ago

AstraZeneca’s market value swells by £4bn after forecast-busting second-quarter results

Revenue beat forecasts by 5%, while operating profit was particularly impressive, coming in some 17% ahead of expectations...

3 weeks, 6 days ago

GSK names former AstraZeneca finance boss as new chairman

Jonathan Symonds will be the man tasked with overseeing the mega merger of GSK and Pfizer’s consumer healthcare businesses...

4 weeks ago

GlaxoSmithKline edges higher as Zejula passes late-stage ovarian cancer study with flying colours

Zejula demonstrated a “statistically significant” improvement in progression free survival – the length of time a patient lives with the disease but it doesn’t get worse...

on 15/7/19

US regulators grant orphan drug status to AstraZeneca’s Imfinzi cancer drug

Imfinzi recently showed in a late-stage study that, when combined with chemotherapy, it had a “clinically meaningful” effect on overall survival...

on 12/7/19

AstraZeneca gets two positive opinions from European Medicines Agency committee

The Committee for Medicinal Products for Human Use (CHMP) recommended that diabetes medicine Forxiga should have its marketing authorisation updated to include cardiovascular data from recent clinical trials...

on 1/7/19

AstraZeneca gets EU approval for Lynparza as ovarian cancer treatment

Pharma giant had been targeting annual peak sales of $2bn for the drug, of which $400mln was from ovarian cancer...

on 18/6/19

AstraZeneca sees further encouraging effects from leukaemia treatment Calquence

Interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people saw no progression of the disease if they were given the drug...

on 17/6/19

AstraZeneca drug for chronic lymphocytic leukaemia successfully navigates phase III trial

The results will “serve as the foundation for regulatory submissions later this year", said AZ’s vice president of oncology, José Baselga...

on 6/6/19

AstraZeneca reports positive results from trial of pancreatic cancer treatment

Results from the trial of Lynparza showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse ...

on 3/6/19
Retail & consumer

Immuno-oncology: All you wanted to know but were too afraid to ask

Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers...

on 27/5/19
Industry & services

Is London's fickle funding appetite part of Lasker's 'disastrous' cycle?

Stock market sage Bernard Lasker once said: “I can feel it coming...A whole new round of disastrous speculation, with all the familiar stages in order: blue-chip boom, then a fad for secondary issues, then an over-the-counter play, then a garbage market in new issues and finally the inevitable crash.”...

on 24/5/19

BHP, AstraZeneca and Shell among world’s top divi payers as shareholders gear up for record year of returns

Asset Manager Janus Henderson is predicting that global dividend pay-outs will reach almost US$1.5trn in 2019...

on 20/5/19

Pharma stocks head south as Trump forces them to display drug prices in TV ads

“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”...

on 9/5/19

AstraZeneca gets US regulatory green light for slow-release diabetes drug

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control...

on 3/5/19

AstraZeneca’s Lynparza set for EU approval as advanced ovarian cancer maintenance treatment

70% of women with ovarian cancer relapse after successful chemo, but Lynparza has been shown to significantly reduce that rate...

on 29/4/19

AstraZeneca first-quarter profits double as product sales revival continues but cash still a worry

The oncology portfolio has helped to turn around Astra’s product sales, which for years had been falling as key drugs went off-patent...

on 26/4/19
Retail & consumer

While UK dividends hit record £19.7bn in first quarter, some FTSE 100 companies could be headed for cuts

Basic measures like dividend cover suggest a number of blue chips might be struggling to maintain their payouts at current levels...

on 19/4/19

AstraZeneca’s new Japanese cancer drug tipped to rack up billions in annual sales

Liberum thinks trastuzumab deruxtecan can generate peak sales of more than US$3bn, given the drug’s potential in a host of cancer indications...

on 5/4/19

AstraZeneca is still not converting top-line momentum into cash-flow, says UBS

Astra has affected a “momentous turnaround” in sales growth, but it has struggled to turn that top-line momentum into cash flow, according to UBS...

on 2/4/19

Circassia on track to achieve underlying profitability in 2020 after recent US approvals

City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”...

on 2/4/19